ERBB2 and endometrial serous adenocarcinoma: In a randomized phase II trial, patients with stage III or IV or recurrent HER2-positive uterine serous carcinoma were randomly assigned to receive carboplatin-paclitaxel for six cycles with or without intravenous trastuzumab until progression or unacceptable toxicity, with improvement in median PFS of 8.0 months in the control arm versus 12.6 months in the group that received trastuzumab (HR 0.44; 90% CI 0.26 to 0.76; p = 0.005) [53].